MX2020013301A - Metodos y composiciones para prevenir o tratar calcifilaxis. - Google Patents

Metodos y composiciones para prevenir o tratar calcifilaxis.

Info

Publication number
MX2020013301A
MX2020013301A MX2020013301A MX2020013301A MX2020013301A MX 2020013301 A MX2020013301 A MX 2020013301A MX 2020013301 A MX2020013301 A MX 2020013301A MX 2020013301 A MX2020013301 A MX 2020013301A MX 2020013301 A MX2020013301 A MX 2020013301A
Authority
MX
Mexico
Prior art keywords
preventing
methods
calciphylaxis
treating
compositions
Prior art date
Application number
MX2020013301A
Other languages
English (en)
Inventor
James A Tumlin
Paul L Darke
John M Rudey
Original Assignee
Epizon Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizon Pharma Inc filed Critical Epizon Pharma Inc
Publication of MX2020013301A publication Critical patent/MX2020013301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona métodos y composiciones para prevenir o tratar (por ejemplo, ralentizar la progresión de, detener, y/o revertir) calcifilaxis en un sujeto que lo necesita y, más particularmente, la invención está relacionada con métodos para usar menaquinona-7 (MK-7) y/o menaquinol-7 (MKH2-7) para prevenir o tratar calcifilaxis en un sujeto con uno más de los siguientes: diabetes, enfermedad renal crónica, insuficiencia renal en etapa terminal, y COPD o un sujeto sometido a hemodiálisis y/o recibiendo terapia de anticoagulante y/o terapia de estatina.
MX2020013301A 2018-06-08 2019-06-07 Metodos y composiciones para prevenir o tratar calcifilaxis. MX2020013301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862682794P 2018-06-08 2018-06-08
PCT/US2019/036139 WO2019237054A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating calciphylaxis

Publications (1)

Publication Number Publication Date
MX2020013301A true MX2020013301A (es) 2021-05-12

Family

ID=68763971

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013301A MX2020013301A (es) 2018-06-08 2019-06-07 Metodos y composiciones para prevenir o tratar calcifilaxis.

Country Status (11)

Country Link
US (7) US10736858B2 (es)
EP (1) EP3801478A4 (es)
JP (1) JP2021527129A (es)
KR (1) KR20210018422A (es)
CN (1) CN112955131A (es)
AU (1) AU2019282421A1 (es)
CA (1) CA3102979A1 (es)
IL (1) IL279246B2 (es)
MX (1) MX2020013301A (es)
SG (1) SG11202012055PA (es)
WO (1) WO2019237054A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279245B2 (en) 2018-06-08 2024-03-01 Epizon Pharma Inc Preparations containing menaquinone-7 (MK-7) and/or menaquinol to prevent tissue calcification
JP2021527129A (ja) 2018-06-08 2021-10-11 エピゾン・ファーマ・インコーポレイテッドＥｐｉｚｏｎ Ｐｈａｒｍａ， Ｉｎｃ． カルシフィラキシスを予防または治療するための方法および組成物
US10822295B2 (en) 2018-09-12 2020-11-03 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
JP2022516567A (ja) * 2019-01-04 2022-02-28 ケイデンス ファーマ アーセー リン吸着剤とビタミンｋとの併用療法
CN112691058A (zh) * 2020-12-31 2021-04-23 玉溪健坤生物药业有限公司 一种含还原型维生素k2的牙膏及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176778A1 (en) 2001-08-03 2005-08-11 Vitak Bv Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification
WO2005030190A1 (en) 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
DE602006020658D1 (de) 2005-06-03 2011-04-28 Nattopharma Asa Verwendung von Vitamin K, um die Verkalkung der Blutgefässe rückgängig zu machen
US20100048704A1 (en) 2006-07-14 2010-02-25 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
BR112013009724A2 (pt) * 2010-11-01 2016-07-19 Viridis Biopharma Pvt Ltd equilíbrio dinâmico do sistemna nervoso autonômo utilizando a vitamina mk-7
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
ES2869202T3 (es) 2012-06-18 2021-10-25 Fresenius Kabi Deutschland Gmbh Sistema de cánula para vía para la punción de vías centrales de acceso subcutáneo
WO2014191466A1 (en) 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
EP3258924A2 (en) 2015-02-20 2017-12-27 VitaK B.V. Vitamin k and capillary function
EA032261B1 (ru) 2015-03-20 2019-04-30 Гносис С.п.А. Способы получения твердых форм менахинолов
IT201700085412A1 (it) 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
US10368858B1 (en) 2018-01-25 2019-08-06 Ring Orthopedics, Inc. Suture passer
IL279245B2 (en) 2018-06-08 2024-03-01 Epizon Pharma Inc Preparations containing menaquinone-7 (MK-7) and/or menaquinol to prevent tissue calcification
JP2021527129A (ja) 2018-06-08 2021-10-11 エピゾン・ファーマ・インコーポレイテッドＥｐｉｚｏｎ Ｐｈａｒｍａ， Ｉｎｃ． カルシフィラキシスを予防または治療するための方法および組成物
US10822295B2 (en) 2018-09-12 2020-11-03 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment

Also Published As

Publication number Publication date
IL279246A (en) 2021-01-31
EP3801478A4 (en) 2022-02-23
US20200306208A1 (en) 2020-10-01
US10987320B2 (en) 2021-04-27
WO2019237054A1 (en) 2019-12-12
CN112955131A (zh) 2021-06-11
JP2021527129A (ja) 2021-10-11
SG11202012055PA (en) 2021-01-28
US10925838B2 (en) 2021-02-23
US20200306206A1 (en) 2020-10-01
IL279246B1 (en) 2023-04-01
US20190374483A1 (en) 2019-12-12
US10736858B2 (en) 2020-08-11
US20200306207A1 (en) 2020-10-01
AU2019282421A1 (en) 2021-01-07
CA3102979A1 (en) 2019-12-12
KR20210018422A (ko) 2021-02-17
EP3801478A1 (en) 2021-04-14
US10940123B2 (en) 2021-03-09
US20200360301A1 (en) 2020-11-19
US20240041794A1 (en) 2024-02-08
IL279246B2 (en) 2023-08-01
US20210378987A1 (en) 2021-12-09
US11065212B2 (en) 2021-07-20
US11793773B2 (en) 2023-10-24

Similar Documents

Publication Publication Date Title
MX2020013301A (es) Metodos y composiciones para prevenir o tratar calcifilaxis.
MX2020013302A (es) Métodos y composiciones para prevenir o tratar calcificación de tejido.
PH12015502275A1 (en) Therapuetic uses of empagliflozin
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
EA033286B1 (ru) Способ лечения или отсрочки развития хронической болезни почек
CL2019001927A1 (es) Composiciones y métodos para el tratamiento de la anemia (divisional solicitud 201702456).
PH12018502593A1 (en) Combinations of linagliptin and metformin
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
MX2016002165A (es) Beneficio de supervivencia en pacientes con tumores solidos con niveles elevados de proteina c reactiva.
MX2016007711A (es) Serpinas modificadas para el tratamiento de trastornos de la coagulacion.
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
MX2019008170A (es) Compuestos útiles para tratar transtornos del tracto gastrointestinal.
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX2022000394A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
BR112015023390A2 (pt) métodos para tratar de doença renal e outros distúrbios
MX2018013203A (es) Ciclodextrinas como procoagulantes.
GR1008769B (el) Οξινο διαλυμα αιμοκαθαρσης με l-ασκορβικο οξυ (βιταμινη c)
ZA202106359B (en) Use of vitamin k in combination with anticoagulants
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
MX2022002993A (es) Rebamipida para usarse en la prevencion y/o tratamiento de la rigidez arterial.
EA201790868A1 (ru) 1,2-бензотиазольные соединения для лечения почечного расстройства